Combining aminolaevulinic acid photodynamic therapy with carbon dioxide laser therapy to treat adult-onset laryngeal papillomatosis: case reports and a literature review

Yanchang Li¹, Fuwang Wei²

¹Department of Dermatovenerology, the Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; ²Department of Thoracic Surgery, Affiliated Cancer Hospital of Guangzhou Medical University, Guangzhou, China

Correspondence to: Fuwang Wei. Department of Thoracic Surgery, Affiliated Cancer Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510095, China. Email: weifuwang909@163.com.

Abstract: This paper describes 3 cases in which 5-aminolaevulinic acid photodynamic therapy (ALA-PDT) was combined with carbon dioxide (CO₂) laser therapy to treat patients with adult-onset laryngeal papillomatosis (ALP). Laryngeal papilloma is the most common benign laryngeal tumor, and is usually caused by human papillomavirus (HPV) types 6 and 11. It has the characteristics of rapid growth and frequent recurrence, and has a tendency of malignant transformation. Moreover, it can spread to the lower respiratory tract, which might lead to a rise in mortality risk. Laryngeal papilloma lesions are frequently found on the vocal cords or in the laryngeal cavity, and the characteristic koilocytosis is dispensable in pathological diagnosis of papilloma. Common symptoms include various degrees of hoarseness and wheezing. In the cases reported herein, all 3 patients suffered a recurrence of ALP following treatment. After the removal of the laryngeal papilloma using a combination of ALA-PDT and CO₂ laser therapy, the patients were cured; there was no recurrence, and no further malignant transformation was found in the 6–12 months postoperative follow-up period. Our experiences show that ALA-PDT combined with CO₂ laser therapy is feasible and effective in the treatment of ALP, and produces no obvious adverse reactions. However, further clinical trials need to be undertaken to confirm the efficacy of this treatment.

Keywords: ALA-PDT; CO₂ laser therapy; laryngeal papillomatosis; case report

Submitted Oct 04, 2020. Accepted for publication Apr 20, 2021.
doi: 10.21037/tcr-20-2985
View this article at: http://dx.doi.org/10.21037/tcr-20-2985

Introduction

Adult-onset laryngeal papilloma (ALP) is the most common laryngeal benign tumor and is usually caused by human papillomavirus (HPV) types 6 and 11 (1). The overall prevalence of ALP is 1.8 per 100,000 people, and the predilection age is 20–40 years (1,2). ALP characteristically manifests with rapid growth and frequent recurrence, and has a tendency of malignant transformation (3). It can spread to the lower respiratory tract, which might lead to a rise in mortality risk (4). Despite the availability of many methods, such as traditional surgery, carbon dioxide (CO₂) laser therapy (3), micro-dehybridization (5), bevacizumab, cidofovir (6), interferon alpha (IFN-α), and newly introduced vaccines, there is no satisfactory and effective treatment for HPV at present (7). However, the application of aminolaevulinic acid photodynamic therapy (ALA-PDT) has produced some promising results in the treatment of condyloma acuminatum and non-melanoma skin cancers (8,9). Additionally, a few recent reports have provided some novel insights into the use of 5-ALA-PDT in the treatment of laryngeal papilloma (8,10,11). In this paper, we present 3 case studies in which patients with ALP were treated with a combination of 5-ALA-PDT and CO₂ laser therapy. Our observations show that this combination is effective in the treatment of ALP and can even eliminate proliferating cancer cells in patients with ALP. We present the following
case in accordance with the CARE reporting checklist (available at http://dx.doi.org/10.21037/tcr-20-2985).

**Case presentation**

The cases include 3 patients with ALP (2 males and 1 female). The patients were diagnosed with ALP between the ages of 31–73, and the disease lasted for 23–36 months from their presentation. Genotyping analysis detected a low risk of HPV 6 and 11, and a high risk of HPV 18. There was no relevant family medical history for any of the patients. All 3 patients had suffered from a recurrence of ALP after previous treatment. The first patient, aged 73, reported progressive hoarseness at the consultation. The patient’s laryngeal papilloma had resurfaced 3 months after 5 surgical resections. In preoperative examinations, moderate to severe atypical hyperplasia and focal cancerization were observed in his histologic sections via electronic laryngoscopy (Figure 1A). The second patient had a relapse of ALP 4 months after 3 microdebrider treatments. The third patient experienced a recurrence of ALP months after CO\textsubscript{2} laser therapy. The common symptoms included various degrees of hoarseness and wheezing. Physical examinations revealed that the ALP lesions were located on the vocal cords or in the laryngeal cavity. The pathological diagnoses were made preoperatively. All 3 patients presented with characteristic koilocytosis in the papilloma, and the second and third patients showed signs of cancerization (Figure 1B).

All procedures performed in studies involving human participants were conducted in accordance with the ethical standards of the institutional committee and with the Helsinki Declaration (as revised in 2013). Written informed consent was obtained from the patients.

**Methods**

The operations were performed under general anesthesia. During the CO\textsubscript{2} laser therapy, double-sac reinforced tracheal intubation and the maintenance of pulmonary ventilation at a low concentration of oxygen (<30%) were necessary. Visible papilloma lesions were removed with a CO\textsubscript{2} laser after a pedestal laryngoscope and a laryngeal endoscope (Figure 2A,B).

Five-aminolevulinic acid (ALA) powder (118 mg/bottle, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.) was dissolved in normal saline to create a 20% concentration solution in the dark. A sterile cotton gauze soaked in ALA solution was placed in the entire laryngeal cavity, including the infraglottic, glottic, and supra-glottic portions. The surgical excision area was covered by the ALA-soaked cotton gauze, with care taken to ensure irregular cavity gaps were not neglected (Figure 2C). The ALA cotton gauze was replaced with fresh gauze every 30 minutes. After a total administration time of 3 hours, the ALA cotton gauze was removed from the laryngeal cavity, and then the surgical excision areas were irradiated at a wavelength of 635 nm using 100–120 J/cm\textsuperscript{2} power for 20 minutes through a columnar optical fiber of a photodynamic therapy instrument (Wuhan Linyun Photoelectronic System Co, Ltd., Wuhan, China).
A follow-up appointment was conducted 3 weeks after the first cycle of treatment. If visible papilloma lesions were absent, 2 extra cycles of PDT irradiation were carried out. If papilloma lesions were present, they were removed using a CO\textsubscript{2} laser, and the irradiation was performed again. After the first cycle of PDT, an inflammatory fibro-polypus was found in case 1 who had been diagnosed with focal cancerization preoperatively. A pathological examination of the lesion revealed the presence of common inflammatory hyperplasia with characteristic koilocytosis, but no further malignant transformation was observed (Figure 3A,B). A follow-up appointment was arranged 6–12 months later, followed by a final cycle of PDT irradiation for all 3 patients. No recurrence was found, and interestingly, the oldest patient showed no sign of neoplasia.

Discussion

The etiology of laryngeal papillomatosis was first described by Ullmann in 1923, and was later confirmed using electron microscopy and polymerase chain reaction techniques (12). ALP is the most common benign laryngeal tumor, with an incidence of approximately 1.8 cases per 100,000 people (2). The condition is caused by HPV infection, including the high-risk types of HPV6/11 and the low-risk types of HPV16/18 (12). HPV can distribute throughout the whole respiratory tract, especially in the larynx, and generate exophytic papillomas, which can lead to symptoms of hoarseness, wheezing, dyspnea, or asphyxia. Clinically, the prognosis is often unsatisfactory, and this condition is often resistant to therapy and recurs frequently. The deregulated expression of viral early genes in basal
epithelial cells and genomic instability, causing secondary host genomic imbalances, are considered key events in the progression of HPV-promoted lesions (12). Notably, malignant transformation has been reported (13,14), and did occur in 1 of our patients. Despite the availability of numerous treatments, such as traditional surgery, CO\(_2\) laser therapy (3), micro-debridization (5), bevacizumab, cidofovir (6), IFN-\(\alpha\), and newly introduced vaccines, there is currently no satisfactory and effective treatment for HPV (7).

In this paper, we examined 3 cases in which patients suffered a recurrence of ALP after receiving treatments including surgery, micro-debridization, and CO\(_2\) laser therapy. These patients were subsequently treated with a combination of ALA-PDT and CO\(_2\) laser therapy. This treatment proved to be extremely efficacious; all of the patients were cured, and there was no second recurrence. However, further clinical trials should be conducted to verify the efficacy of this treatment.

In recent years, PDT has been approved to treat lung cancer, esophageal cancer, and Barrett’s esophagus (15,16). The application of ALA-PDT in the treatment of condyloma acuminatum, HPV infection, and non-melanoma skin cancers has produced some promising results (8,9). ALA-PDT can effectively eliminate latent or subclinical HPV infections, and thus can reduce the recurrence of condyloma acuminatum (17). PDT induces the death of HPV-infected cells by apoptosis or necrosis after the laser excitation of the photosensitizer (18). The photosensitizer is activated by light and interacts with molecular oxygen to produce reactive singlet oxygen, resulting in the destruction of proliferating cancer cells (15). In 2014, Zhou et al. first successfully used PDT to treat juvenile laryngeal papillomatosis (19). Zhang later showed that ALA-PDT with a self-retaining laryngoscope combined with CO\(_2\) laser therapy is safe and effective for clearing juvenile and adult laryngeal papilloma (11). Similarly, topical ALA-PDT can significantly reduce the recurrence of ALP and improve its cure rate (10).

In the present study, we used ALA-PDT to treat 3 patients with ALP, who were all cured. The patients all underwent self-retaining laryngoscopy combined with CO\(_2\) laser therapy previously. According to Liang et al. (10), ALP relapses at a rate of 15.4% after ALA-PDT combined with CO\(_2\) laser therapy. After treatment, the focal cancerization in the oldest patient transformed into common inflammatory hyperplasia, and no further malignant transformation was found. ALA-PDT can selectively eliminate abnormally proliferating cells without damaging healthy tissue (15). Further, synchiae formation of the anterior commissure after CO\(_2\) laser therapy can be avoided to some degree (20). No glottic synchiae was observed following treatment in our cases. In addition to the above-described mechanism of action, ALA-PDT increases CD4+, CD4+/CD8+ and IFN-\(\gamma\), and reduces CD8+, IL-4, and IL-10 in HPV-infected cells, which may also contribute to the curing of intractable laryngeal papillomatosis (21).

The main adverse reactions of PDT include inflammatory reactions, local edema, liver toxicity, pain, and phototoxicity (22). Most of these reactions are mild, and
patients recover quickly (8,23). Notably, no complications were recorded in our patients. Due to the high risk of malignant transformation in ALP (24), we are of the view that histological examinations should be undertaken before the removal of lesions during each cycle of ALA-PDT.

In conclusion, ALA-PDT combined with CO₂ laser therapy is feasible and effective for the treatment of ALP, and can obtain a good curative effect. However, further clinical trials need to be undertaken to determine whether ALA-PDT alters the course of laryngeal papillomatosis or adds any benefits to the surgical treatment of laryngeal papillomatosis.

Acknowledgments

The authors acknowledge AME Editing Service for editing the manuscript.

Funding: None.

Footnote

Reporting Checklist: The authors have completed the CARE reporting checklist. Available at http://dx.doi.org/10.21037/tcr-20-2985

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tcr-20-2985). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional committee and with the Helsinki Declaration (as revised in 2013). Written informed consent was obtained from the patients.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license).

See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Derkay CS, Bluher AE. Update on Recurrent Respiratory Papillomatosis. Otolaryngol Clin N Am 2019;52:669-79.
2. Armstrong LR, Derkay CS, Reeves WC. Initial results from the national registry for juvenile-onset recurrent respiratory papillomatosis. RRP Task Force. Arch Otolaryngol Head Neck Surg 1999;125:743-8.
3. Dedo HH, Yu KC. CO₂ laser treatment in 244 patients with respiratory papillomatosis. Laryngoscope 2001;111:1639-44.
4. Derkay CS. Recurrent respiratory papillomatosis. Laryngoscope 2001;111:57-69.
5. Pasquale K, Wiatrak B, Woolley A, et al. Microdebrider versus CO₂ laser removal of recurrent respiratory papillomas: a prospective analysis. Laryngoscope 2003;113:139-43.
6. Jackowska J, Klimza H, Piersiala K, et al. Outcomes of bevacizumab and cidofovir treatment in HPV-associated recurrent respiratory papillomatosis - review of the literature. Otolaryngol Pol 2018;72:1-8.
7. Naren N. Venkatesan, Harold S. Pine, Michael P. Underbrink. Recurrent Respiratory Papillomatosis. Otolaryngol Clin N Am 2012;45:671-94.
8. Ao C, Xie J, Wang L, et al. 5-aminolevulinic acid photodynamic therapy for anal canal condyloma acuminatum: A series of 19 cases and literature review. Photodiagnostics Photodyn Ther 2018;23:230-4.
9. Chow EP, Lin AC, Read TR, et al. Ratio of anogenital warts between different anatomical sites in homosexual and heterosexual individuals in Australia, 2002–2013: implications for susceptibility of different anatomical sites to genital warts. Epidemiol Infect 2015;143:1495-9.
10. Liang F, Han P, Chen R, et al. Topical 5-aminolevulinic acid photodynamic therapy for laryngeal papillomatosis treatment. Photodiagnostics Photodyn Ther 2019;28:136-41.
11. Zhang Y, Yang Y, Zou X, et al. 5-Aminolevulinic Acid Photodynamic Therapy combined with CO₂ laser therapy in treatment of laryngeal papilloma: Case report. Photodiagnostics Photodyn Ther 2016;14:131-3.
12. Carifi M, Napolitano D, Morandi M, et al. Recurrent respiratory papillomatosis: current and future perspectives. Ther Clin Risk Manag 2015;11:731-8.
13. Schraff S, Derkay CS, Burke B, et al. American Society of Pediatric Otolaryngology members’ experience with
recurrent respiratory papillomatosis and the use of adjuvant therapy. Arch Otolaryngol Head Neck Surg 2004;130:1039-42.

14. Gorgoulis V, Rassidakis G, Karameris A, et al. Expression of p53 protein in laryngeal squamous cell carcinoma and dysplasia: possible correlation with human papillomavirus infection and clinicopathological findings. Virchows Arch 1994;425:481-9.

15. Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer 2003;3:380-7.

16. Dougherty TJ, Gomer CJ, Henderson BW, et al. Photodynamic therapy. J Natl Cancer Inst 1998;90:889-905.

17. Zhili Hu, Junpeng Li, Hui Liu, et al. Treatment of latent or subclinical Genital HPV Infection with 5-aminolevulinic acid-based photodynamic therapy. Photodiagnosis Photodyn Ther 2018;23:362-4.

18. Agostinis P, Berg K, Cengel KA, et al. Photodynamic therapy of cancer: an update. CA Cancer J Clin 2011;61:250-81.

19. Zhou C, Sun B, Wang F, et al. Coblation plus photodynamic therapy (PDT) for the treatment of juvenile onset laryngeal papillomatosis: case reports. World J Surg Oncol 2014;12:275-80.

20. Papaspyrou G, Schick B, Papaspyrou S, et al. Retrospective analysis of laser vs other therapeutic modalities for laryngeal papillomatosis: European multicenter study. J BUON 2016;21:1274-8.

21. Meng X, Li Y, Luan H, et al. Therapeutic effect of photodynamic therapy combined with imiquimod in the treatment of anal condyloma acuminatum and its effect on immune function. Exp Ther Med 2018;16:3909-12.

22. Feyh J, Kastenbauer E. Treatment of laryngeal papillomatosis with photodynamic laser therapy. Laryngorhinootologie 1992;71:190-2.

23. Mi X, Chai W, Zheng H, et al. A randomized clinical comparative study of cryotherapy plus photodynamic therapy vs. cryotherapy in the treatment of multiple condylomata acuminata. Photodermatol Photoimmunol Photomed 2011;27:176-80.

24. Rady PL, Schnadig VJ, Weiss RL, et al. Malignant transformation of recurrent respiratory papillomatosis associated with integrated human papillomavirus type 11 DNA and mutation of P53. Laryngoscope 1998;108:735-40.

Cite this article as: Li Y, Wei F. Combining aminolaevulinic acid photodynamic therapy with carbon dioxide laser therapy to treat adult-onset laryngeal papillomatosis: case reports and a literature review. Transl Cancer Res 2021. doi: 10.21037/tcr-20-2985